NCT02941783Completed
Drug Use Investigation of Kovaltry in Hemophilia A Patients
Special Drug Investigation of Kovaltry in Hemophilia A Patients
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The objective in this study is collecting post-marketing information on the safety and efficacy of Kovaltry under the routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 230 (actual)
- First submitted
- 20 Oct 2016
- Start date
- 30 Nov 2016
- Primary completion date
- 23 Mar 2022
- Lead sponsor
- Bayer
- Diseases
- Haemophilia
- NCT number
- NCT02941783
What you commit to
- Study type: Observational
- Participants enrolled: 230
- From 30 Nov 2016 to the primary completion date, 23 Mar 2022
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A
Other
- Patients participating in an investigational program with interventions outside of routine clinical practice.
Who the study is looking for
- Male and female hemophilia A patients.
- Patients for whom the decision to treat with Kovaltry was determined prior to enrollment in the study.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.